Chanticleer
CSL’s second seamless transition in 30 years from one CEO to another internal candidate is a blueprint for other complex, global corporations.
Global biotechnology company CSL keeps giving its ASX 200 counterparts masterclasses in CEO succession planning.
It did it in February 2013 with the appointment of Paul Perreault to replace Brian McNamee, who is now chairman of the $143 billion company.
Fetching latest articles
Original URL: https://www.afr.com/chanticleer/perreault-leaves-csl-in-good-hands-20221213-p5c61h
